Phio Pharmaceuticals Q3 2026 Earnings Date & Estimates

Phio Pharmaceuticals (NASDAQ:PHIO) is a clinical-stage biotechnology company focused on developing immuno-oncology treatments based on its INTASYL self-delivering RNAi technology. The platform is designed to enable small interfering RNA (siRNA) molecules to enter cells without the use of conventional delivery vehicles and to reduce the expression of selected genes involved in cancer biology and immune-system activity.

The company’s pipeline has included product candidates intended to improve the ability of immune cells to recognize and destroy tumors. Its programs have included PH-762, an investigational therapy designed to inhibit PD-1 expression in immune cells, and other INTASYL-based candidates targeting pathways such as TIGIT and the immunosuppressive tumor microenvironment. Phio has evaluated its technology in preclinical research and early-stage clinical development, including potential use as a treatment administered directly into tumors or in combination with other immunotherapies.

Phio Pharmaceuticals was previously known as RXi Pharmaceuticals and adopted its current name in 2017. The company is based in Marlborough, Massachusetts, and has focused primarily on oncology research and development. As a development-stage biotechnology business, its activities have centered on advancing its proprietary platform and product candidates rather than selling approved commercial medicines.